Pulmonary Fibrosis Awareness Month may be coming to a close, but it's important to keep the momentum going, columnist Sam Kirton says.

September is Pulmonary Fibrosis Awareness Month. Pulmonary fibrosis is a disease marked by scarring in the lungs.

BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease characterized by unexplained ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.

Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...

Idiopathic Pulmonary Fibrosis (IPF) leads to thickening and stiffening of lung tissue, impairing gas exchange and causing ...

The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) has shown clinically meaningful responses in pretreated patients with extensive-stage ... the case. Idiopathic pulmonary fibrosis ...

IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

GRI Bio, Inc. is a clinical-stage biopharmaceutical company ... as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is ...